Navigation Links
BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
Date:3/2/2011

ithout limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, results of the clinical development for and regulatory review of BEMA Buprenorphine/Naloxone) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publically update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.  Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
2. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
3. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
4. Novavax Licenses Recombinant VLP Influenza Vaccine to LG Life Sciences for South Korea and Other Countries
5. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
6. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
7. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
8. Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
9. Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers
10. Medical Devices and Diagnostics Analyst Joins MLV to Further Expand its Coverage of the Life Sciences Sector
11. OXIS International to Present at the Lippert/Heilshorn Life Sciences and Medtech Virtual Conference on February 17
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- The ... basis of products, methods, applications, end users, and ... growth in the microbial identification market. This favorable ... costs (per test) and the time required for ... continuous technological advancements. Furthermore, genotypic methods have high ...
(Date:7/29/2014)... OAKS, Calif., July 29, 2014 Amgen (NASDAQ: ... the second quarter of 2014. Key results include: ... with 8 percent product sales growth driven by strong ... Kyprolis ® (carfilzomib), Prolia ® (denosumab) and ... 25 percent to $2.37, driven by higher revenues and ...
(Date:7/29/2014)...  Express Scripts Holding Company (Nasdaq: ESRX ... Express Scripts stockholders of $515.2 million, or $0.67 per ... in Table 4, was $1.23 for the second quarter. ... serve our clients with scale, alignment and innovative solutions to ... outcomes of our members," stated George Paz, chairman and chief ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
... Wound Care Innovations, LLC,a subsidiary of Wound ... an evidence based study with a NE podiatric ... care collagen,product, CellerateRx(R), on diabetic venous ulcers. "According ... and Prevention, diabetes now,affects nearly 24 million people ...
... Clinical Program Leverages Quark,s RNAi Technology, FREMONT, ... pharmaceutical company discovering and developing novel,RNA interference (RNAi)-based ... patient dosing in a Phase II trial,evaluating, ... (DME)., PF-4523655 is a novel siRNA drug ...
Cached Medicine Technology:Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers 2Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 2Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 3Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 4
(Date:7/29/2014)... TUESDAY, July 29, 2014 (HealthDay News) -- Although the ... wounds usually heal well if left alone, an expert ... signs of an adverse reaction to a brown recluse ... the Tennessee Poison Center, particularly since these potentially dangerous ... is hard for us to do nothing. The [bite] ...
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... leading pediatricians have joined our network, CarePoint Health ... and Dr. Sushma Kaki. Hundreds of highly skilled ... a comprehensive network of top doctors and practices ... specialties. This latest acquisition represents CarePoint Health’s commitment ...
(Date:7/29/2014)... HealthDay Reporter TUESDAY, July 29, ... just a single dose of the hormone oxytocin quickly improved ... report. Known as the "love hormone," oxytocin has been ... and between mothers and their children. In this study, ... the brain that has long been associated with the processing ...
(Date:7/29/2014)... Summer is here, and that means it’s time to ... in a pool or laying out on the beach. However, warm ... Puppy Store is here to help pet owners protect their dogs ... impossible to completely keep fleas and ticks at bay, but there ... their pets coming into contact with fleas and ticks. , Flea ...
(Date:7/29/2014)... Bret Busacker , a partner in ... been appointed to the Board of Directors for the ... an experienced business attorney with a focus on employee ... a wide spectrum of topics regarding equity and incentive ... concerns. His clients include public and private businesses, governmental ...
Breaking Medicine News(10 mins):Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2
... state that there are insufficient doctors specializing in sports medicine ... Olympics// that is to be hosted by UK. ,Presently ... specialist each, for the treatment of treat sports injuries as ... ,According to the Royal College of Physicians specialists ...
... the American Red Cross yet again with a whopping fine ... blood collection techniques.// The Red Cross (ARC), which is responsible ... has been under the vigilance of the government since 1993, ... enhancing the quality control system., ,This fine slapped ...
... Cocaine, in concentrations commonly sold on the street, causes ... – a process causing heart enlargement that can ultimately ... of South Florida College of Medicine and James A. ... in the July 2006 issue of the Journal of ...
... genetics of a potentially lethal heart rhythm defect that ... have greatly narrowed //the hunt for the specific genetic ... new findings, described in the July issue of the ... of tests to identify those at risk for arrhythmogenic ...
... increase risk of developing a disability in later life. ... to reduce the nation’s disability levels, // according to ... about risks with exercise, home safety and health assessments ... run, found researchers led by Vicki Freedman, Ph.D., a ...
... the potential to suppress tumor growth also plays a major ... p16INK4a caused cell to grow old and work poorly as ... their age even when transplanted into young mice. Other cells ... older cells. ,Teams from the medical schools at ...
Cached Medicine News:Health News:Sports Doctors too few for 2012 Olympics 2Health News:Researchers Identify Key Step in Cocaine-Induced Heart Enlargement, Sudden Death 2Health News:Closing in on Lethal Heart Rhythm in Young Athletes 2Health News:Closing in on Lethal Heart Rhythm in Young Athletes 3Health News:Preventing Falls May Be Key to Avoiding Disability in Elderly 2Health News:Gene May Regulate Cellular Aging 2Health News:Gene May Regulate Cellular Aging 3
... are available in two tip ... tip with staggered eyes, and ... types of catheter valve options, ... fingertip control with virtually no ...
... are available in two tip ... tip with staggered eyes, and ... types of catheter valve options, ... fingertip control with virtually no ...
Sterile Single Loop Pediatric Suction Catheters with TOUCH-TROL Valve...
Catheter Suction 14FR Sterile W/Control Valve...
Medicine Products: